Clicky

Oric Pharmaceuticals, Inc.(ORIC)

Description: ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.


Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Occupational Safety And Health Solid Tumors Oncology Immunotherapy Treatment Of Cancer Cancer Treatment Chemotherapy Antineoplastic Drugs Specialty Drugs Precision Medicine Cancer Therapeutics Cd73

Home Page: www.oricpharma.com

ORIC Technical Analysis

240 East Grand Avenue
South San Francisco, CA 94080
United States
Phone: 650 388 5600


Officers

Name Title
Dr. Richard A. Heyman Ph.D. Co-Founder, Independent Chairman & Member of Scientific Advisory Board
Dr. Jacob M. Chacko M.B.A., M.D. Pres, CEO & Director
Mr. Dominic G. Piscitelli CPA, CPA, M.B.A. Chief Financial Officer
Dr. Pratik S. Multani M.D., M.S. Chief Medical Officer
Dr. Charles L. Sawyers B.A., BA, M.D., Ph.D. Co-Founder & Member of Scientific Advisory Board
Dr. Scott W. Lowe Ph.D. Co-Founder & Member of Scientific Advisory Board
Dr. Lori Sickels Friedman Ph.D. Chief Scientific Officer
Dr. Christian V. Kuhlen Esq., J.D., M.D. Gen. Counsel
Mr. Daniel Iazzetti VP & Head of People
Dr. Edna Chow Maneval Sr. VP of Clinical Devel.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.6485
Price-to-Sales TTM: 0
IPO Date: 2020-04-24
Fiscal Year End: December
Full Time Employees: 88
Back to stocks